167 related articles for article (PubMed ID: 14569947)
61. [Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Hebbar M; Hecquet B; Vanlemmens L; Lecomte S; Pion JM; Adenis A; Bonneterre J
Bull Cancer; 1995 Jan; 82(1):67-9. PubMed ID: 7742620
[TBL] [Abstract][Full Text] [Related]
62. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
63. Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Kim K; Chie EK; Jang JY; Kim SW; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
Jpn J Clin Oncol; 2009 Feb; 39(2):111-5. PubMed ID: 19060294
[TBL] [Abstract][Full Text] [Related]
64. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
[TBL] [Abstract][Full Text] [Related]
65. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
[TBL] [Abstract][Full Text] [Related]
66. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
[TBL] [Abstract][Full Text] [Related]
67. Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy.
Sagar SM; Bayliss MA; Chong SL; Retsas S
Clin Oncol (R Coll Radiol); 1991 May; 3(3):183. PubMed ID: 1829958
[No Abstract] [Full Text] [Related]
68. Comparative activity of antiemetic drugs.
Jordan K; Schmoll HJ; Aapro MS
Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
[TBL] [Abstract][Full Text] [Related]
69. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
[TBL] [Abstract][Full Text] [Related]
70. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
71. The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients after ear-nose-throat surgery.
Davis PJ; Fertal KM; Boretsky KR; Fedel GM; Ingram MD; Woelfel SK; Hoffmann PC; Gurnaney H; Young MC
Anesth Analg; 2008 Apr; 106(4):1117-21, table of contents. PubMed ID: 18349181
[TBL] [Abstract][Full Text] [Related]
72. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
[TBL] [Abstract][Full Text] [Related]
73. [Anti-emetic effects of ondansetron hydrochloride throughout courses of cytotoxic chemotherapy].
Nishida T; Yakushiji M; Ohizumi K; Noda S; Rikimaru T; Matsuoka K
Gan To Kagaku Ryoho; 2002 Jan; 29(1):81-7. PubMed ID: 11816483
[TBL] [Abstract][Full Text] [Related]
74. [The management of vomiting and nausea with zofran during the chemotherapy of malignant tumors].
Seliuzhitskiĭ IV; Eliseev SN; Ivanov AI
Voen Med Zh; 1994 Oct; (10):34-6. PubMed ID: 7831851
[No Abstract] [Full Text] [Related]
75. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
Chen PT; Liaw CC
Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417
[TBL] [Abstract][Full Text] [Related]
76. [Optimal timing of granisetron administration for the prevention of carboplatin-induced acute emesis].
Yamauchi H; Ishikawa H; Suzuki S; Nagaji M; Fujiwara K; Kohno I
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2217-21. PubMed ID: 10635307
[TBL] [Abstract][Full Text] [Related]
77. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
78. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
79. Haloperidol vs. ondansetron for the prevention of postoperative nausea and vomiting following gynaecological surgery.
Aouad MT; Siddik-Sayyid SM; Taha SK; Azar MS; Nasr VG; Hakki MA; Zoorob DG; Baraka AS
Eur J Anaesthesiol; 2007 Feb; 24(2):171-8. PubMed ID: 16938159
[TBL] [Abstract][Full Text] [Related]
80. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy.
Castelo-Branco C; Nomdedeu B; Camus A; Mercadal S; Martínez de Osaba MJ; Balasch J
Fertil Steril; 2007 Mar; 87(3):702-5. PubMed ID: 17173900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
